All Posts By

Lehi Vidigal

Lehi Vidigal
0
PRESS RELEASES
06/2023

Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023

Denifanstat was well-tolerated and met primary endpoint in planned interim readout with 67% of treated patients achieving ≥30% reductions in liver fat at week 26 compared to 18% placebo (p<0.001)…
Read More
Lehi Vidigal
0
NASH
06/2023

Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial

EASL International Liver Congress
Read More
Lehi Vidigal
0
PRESS RELEASES
06/2023

Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023

San Mateo, Calif., June 7, 2023 – Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that it will present interim data from the…
Read More